Want to keep learning?

This content is taken from the UEA (University of East Anglia)'s online course, Using Personalized Medicine and Pharmacogenetics. Join the course to learn more.

Skip to 0 minutes and 1 second Abe is thirteen years old. He’s been a leading member of his high school football team since joining Central Norwich School two years ago. His parents moved from Ethiopia to England in 1999. On Saturday afternoon Abe was playing football but sustained an ankle injury. He was given ibuprofen for pain relief but by the evening he was still in severe discomfort and he was tearful. So his parents took him to the local A&E department. While he was waiting for an x-ray his parents asked the triage nurse if Abe could have some codeine because of his extreme pain. However, the clinical pharmacist raised concerns about the risk of toxicity if Abe is a rapid metaboliser of codeine.

Skip to 0 minutes and 47 seconds His age and ethnicity could have an impact on his individual pharmacokinetic profile.

Clinical scenario: using genetic tests to predict efficacy or toxicity

Please read the scenario and then watch the video. Then identify any terminology and concepts that you want to know more about. These will be addressed in our tutorials and suggested background reading.

The clinical scenario

Abai is a 13 year old boy of African ethnicity who presents to Emergency Department complaining of a very painful ankle after a heavy tackle in a football match.

His parents gave him some ibuprofen but the pain has not resolved. They ask if Abai could be given stronger analgesia, such as codeine. However, the clinical pharmacists raises concerns about toxicity with codeine in children.

Share this video:

This video is from the free online course:

Using Personalized Medicine and Pharmacogenetics

UEA (University of East Anglia)